Abbott Prism Hepatitis B, C And HTLV I/II Assays Gain FDA Panel Nod
This article was originally published in The Gray Sheet
Executive Summary
Use of Abbott Laboratories' Prism automated blood screener in conjunction with its hepatitis B surface antigen assay detected an additional 26.3 potentially infectious blood units annually, the company told FDA's Blood Products Advisory Committee Sept 17.